Jan 9, 2022 | Press Release
Agreement grants a license to Exact Sciences for OncXerna’s Xerna™ TME Panel adding to itscomprehensive tumor profiling solution, GEM ExTra® Arrangement expands Exact Sciences’ ability to support immuno-oncology clinical development programs MADISON, Wis., and...
Oct 23, 2021 | Press Release
62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker negative patients using the XernaTM TME Panel 9.2 month vs. 3.9 month median progression free survival in biomarker positive vs. biomarker negative patients using...
Sep 16, 2021 | Press Release
22% vs. 4% response rates with bavituximab-pembrolizumab in biomarker positive vs. negative patients using the XernaTM TME Panel Waltham, MA. September 16, 2021 – Oncxerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression...
Aug 17, 2021 | Press Release
Waltham, MA. August 17, 2021 – OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies, today announced the appointment of Evan...
Aug 9, 2021 | Press Release
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab Agreements include a non-exclusive license for QIAGEN to the...
Jul 19, 2021 | Press Release
Waltham, MA. July 19, 2021 – OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura...